Calliditas Therapeutics AB Total Revenue

The latest total revenue for CALT is $1.6B as of June 2024. That compares with $1.1B in the prior-year period — up 39.3% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Calliditas Therapeutics AB's historical trend and sector peers before judging valuation or financial health.

Over the past year, CALT's total revenue moved from $1.1B to $1.6B — a 39.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Calliditas Therapeutics AB's operating scale or balance-sheet position.

Against Healthcare companies, CALT currently prints $1.6B for total revenue, while the sector average sits near $110B. That is roughly 98.6% below the sector mean. Large gaps often invite a closer look at Calliditas Therapeutics AB's growth, margins, and balance sheet.

A total revenue figure of $1.6B for CALT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting CALT's total revenue ($1.6B), review year-over-year change from $1.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.